Aspire Biopharma Holdings (ASBP) Cash from Financing Activities (2021 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Cash from Financing Activities of $7.9 million for Q1 2026, up 155.03% year-over-year from $3.1 million in Q1 2025, and up 47852.89% quarter-over-quarter from -$16526.0 in Q4 2025.
Aspire Biopharma Holdings (ASBP) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Cash from Financing Activities for 6 consecutive years, with $7.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 155.03% year-over-year to $7.9 million; the TTM figure through Mar 2026 stood at $10.7 million (up 243.29% YoY), while the FY2025 annual figure was $5.9 million, up 2199.19% from the prior year.
- Cash from Financing Activities advanced to $7.9 million in Q1 2026 per ASBP's latest filing, from -$16526.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $296.6 million in Q1 2022 and bottomed at -$632968.0 in Q3 2023.
- Historically, Cash from Financing Activities has averaged $28.2 million across 5 years, with a median of $229084.0 in 2024.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities plunged 416.0% — and 2025, when it surged 1250.79%.
- Aspire Biopharma Holdings' Cash from Financing Activities stood at $296.6 million in 2022, then slumped by 99.95% to $155848.0 in 2023, then slumped by 416.0% to -$492477.0 in 2024, then surged by 96.64% to -$16526.0 in 2025, then soared by 47852.89% to $7.9 million in 2026.
- Business Quant data shows ASBP's Cash from Financing Activities at $7.9 million in Q1 2026, -$16526.0 in Q4 2025, and $2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | 8.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.43 Mn |
| Jun 30, 2026 | 8.43 Mn |
| Mar 31, 2026 | 7.89 Mn |
| Mar 31, 2026 | 7.89 Mn |
| Dec 31, 2025 | -16,526.00 |
| Dec 31, 2025 | -16,526.00 |
| Sep 30, 2025 | 2.85 Mn |
| Sep 30, 2025 | 2.85 Mn |
| Mar 31, 2025 | 3.09 Mn |
| Mar 31, 2025 | 3.09 Mn |
| Dec 31, 2024 | -492,477.00 |
| Dec 31, 2024 | -492,477.00 |
| Sep 30, 2024 | 492,477.00 |
| Sep 30, 2024 | 492,477.00 |
| Jun 30, 2024 | 28,561.00 |
| Jun 30, 2024 | 28,561.00 |
| Mar 31, 2024 | 229,084.00 |
| Mar 31, 2024 | 229,084.00 |
| Dec 31, 2023 | 155,848.00 |
| Dec 31, 2023 | 155,848.00 |